Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angel Guzman-Perez

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1Robert L Dow, Jian-Cheng Li, Michael P Pence, et al.
Journal of Medicinal Chemistry|January 17, 2025
Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung CancerBenjamin C Milgram, Deanna R Borrelli, Natasja Brooijmans, et al.
Journal of Medicinal Chemistry|March 5, 2016
Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo ActivityLaurie B Schenkel, Philip R Olivieri, Alessandro A Boezio, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2014
Identification of a novel conformationally constrained glucagon receptor antagonistEsther C Y Lee, Meihua Tu, Benjamin D Stevens, et al.
Bioorganic & Medicinal Chemistry Letters|November 29, 2011
A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicityKevin J Filipski, Jianwei Bian, David C Ebner, et al.
Journal of Medicinal Chemistry|May 25, 2013
Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitorsHoward Bregman, Nagasree Chakka, Angel Guzman-Perez, et al.
ACS Medicinal Chemistry Letters|April 16, 2020
Discovery of [1,2,4]Triazolo[1,5-<i>a</i>]pyridine Derivatives as Potent and Orally Bioavailable RORγt Inverse AgonistsRyota Nakajima, Hiroyuki Oono, Sakae Sugiyama, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2013
The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitusAngel Guzman-Perez, Jeffrey A Pfefferkorn, Esther C Y Lee, et al.
Journal of Medicinal Chemistry|December 22, 2016
The Discovery and Hit-to-Lead Optimization of Tricyclic Sulfonamides as Potent and Efficacious Potentiators of Glycine ReceptorsHoward Bregman, Jeffrey R Simard, Kristin L Andrews, et al.
Journal of Medicinal Chemistry|December 4, 2013
Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitorsZihao Hua, Howard Bregman, John L Buchanan, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1Robert L Dow, Jian-Cheng Li, Michael P Pence, et al.
Journal of Medicinal Chemistry|January 17, 2025
Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung CancerBenjamin C Milgram, Deanna R Borrelli, Natasja Brooijmans, et al.
Journal of Medicinal Chemistry|March 5, 2016
Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo ActivityLaurie B Schenkel, Philip R Olivieri, Alessandro A Boezio, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2014
Identification of a novel conformationally constrained glucagon receptor antagonistEsther C Y Lee, Meihua Tu, Benjamin D Stevens, et al.
Bioorganic & Medicinal Chemistry Letters|November 29, 2011
A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicityKevin J Filipski, Jianwei Bian, David C Ebner, et al.
Journal of Medicinal Chemistry|May 25, 2013
Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitorsHoward Bregman, Nagasree Chakka, Angel Guzman-Perez, et al.
ACS Medicinal Chemistry Letters|April 16, 2020
Discovery of [1,2,4]Triazolo[1,5-<i>a</i>]pyridine Derivatives as Potent and Orally Bioavailable RORγt Inverse AgonistsRyota Nakajima, Hiroyuki Oono, Sakae Sugiyama, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2013
The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitusAngel Guzman-Perez, Jeffrey A Pfefferkorn, Esther C Y Lee, et al.
Journal of Medicinal Chemistry|December 22, 2016
The Discovery and Hit-to-Lead Optimization of Tricyclic Sulfonamides as Potent and Efficacious Potentiators of Glycine ReceptorsHoward Bregman, Jeffrey R Simard, Kristin L Andrews, et al.
Journal of Medicinal Chemistry|December 4, 2013
Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitorsZihao Hua, Howard Bregman, John L Buchanan, et al.
Pageof 5